Alpha Diallo
0
All posts from Alpha Diallo
Alpha Diallo in Alpha Diallo,

Rebate Agreement between Vivus and CVS

VIVUS, Inc. (NASDAQ:VVUS) has reached an agreement with CVS Caremark Corporation (NYSE:CVS) to allow its diet drug Qsymia to be available for co-payments ranging from $15 to $75 for patients with obesity coverage at CVS. Since Qsymia came to market, investors were not lukewarm to the drug because it was expensive and lacked insurance coverage. With Obamacare now mandating insurance coverage, more people will have access to Qsymia. In addition, the deal with CVS makes the drug affordable to the masses.